New York, New York (PRWEB) April 01, 2014
As Lipitor lawsuits (http://www.thelipitorlawsuit.com/ ) filed on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin continue to mount in federal court, Bernstein Liebhard LLP notes the release of two new studies which suggest that an experimental cholesterol-lowering drug currently in development could become an alternative to statins like Lipitor. According to a report from TechTimes.com, the research was presented March 29th at the 63rd Annual Scientific Session of the American College of Cardiology (ACC). One of the studies found that patients who were treated with the experimental medication, known as evolocumab, reduced their LDL, or bad, cholesterol by up to 57% after just three months of treatment. The second study observed a similar reduction in LDL cholesterol in patients who received monthly evolocumab injections for one year compared to subjects who received a placebo. *
“Hundreds of people have filed lawsuits in recent months that allege the use of Lipitor caused diabetes. In light of the health concerns cited in these Lipitor lawsuits, the possibility that an alternative medication might be available at some point in the future is certainly an interesting development,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The firm is currently offering free Lipitor lawsuit consultations to anyone who may have been harmed by this medication.
Lipitor Diabetes Allegations
In March 2012, the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statins like Lipitor to add new information to their product labels regarding a possible increased risk of Type 2 diabetes. The agency acted after a study published in JAMA: Internal Medicine in January reported that post-menopausal women treated with drugs like Lipitor were at increased risk of developing new-onset Type 2 diabetes. * *
In May 2013, the British Medical Journal also reported an association between Lipitor and diabetes, finding that patients who took the drug had a 22 percent increased risk of new-onset diabetes.***
Court documents indicate that since the FDA mandated the label change, more than 270 Lipitor lawsuits have been filed in a multidistrict litigation underway in U.S District Court, District of South Carolina on behalf of individuals who allege their use of the statin caused Type 2 diabetes. Among other things, plaintiffs allege that Pfizer Inc. knew of the association between Lipitor and diabetes, but concealed this information in order to protect sales of the medication. The lawsuits also claim that the cautions added to the Lipitor label following the FDA’s March 2012 order remain inadequate. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
Alleged victims of Lipitor and diabetes may be eligible for compensation for medical bills, lost wages, pain and suffering and more. Learn more about Lipitor lawsuits at Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*techtimes.com/articles/4984/20140401/new-experimental-cholesterol-drug-by-amgen-may-be-better-than-lipitor.htm, TechTimes.com, April 1, 2014
**archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
***&bmj.com/content/346/bmj.f2610, BMJ, May 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com